All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

terizidone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	2602	25683-71-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: terizidone terivalidin terizidon	minor descriptor (1975-1984); on-line & Index Medicus search OXAZOLES (1975-1984); RN given refers to parent cpd without isomeric designation Molecular weight: 302.29 Formula: C14H14N4O4 CLOGP: 0.56 LIPINSKI: 0 HAC: 8 HDO: 2 TPSA: 101.38 ALOGS: -3.08 ROTB: 4

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2B,EIF2AK3,GRK2,PDK1,PDK2,PRKDC	6
kinase-selectivity-class	GRK2,PDK1,TEK	3
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Polyneuropathy	62.02	50.46	16	568	19325	90608538
Neuropathy peripheral	59.98	50.46	25	559	136945	90490918
Myelosuppression	57.79	50.46	19	565	53572	90574291
Myopathy	57.37	50.46	14	570	13504	90614359

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Electrocardiogram QT prolonged	96.58	56.28	32	505	47913	42572885
Drug resistance	65.37	56.28	22	515	34226	42586572
Polyneuropathy	60.62	56.28	18	519	18643	42602155
Myelosuppression	57.99	56.28	21	516	40440	42580358

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Polyneuropathy	125.00	48.93	34	1087	31978	110556200
Myelosuppression	110.99	48.93	40	1081	94300	110493878
Electrocardiogram QT prolonged	94.61	48.93	37	1084	108923	110479255
Drug resistance	85.82	48.93	29	1092	56345	110531833
Anaemia	75.52	48.93	54	1067	547032	110041146
Neuropathy peripheral	70.85	48.93	35	1086	179242	110408936
Psychotic disorder	53.82	48.93	20	1101	50917	110537261
Bicytopenia	50.18	48.93	12	1109	6712	110581466

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J04AK03	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Other drugs for treatment of tuberculosis
CHEBI has role	CHEBI:33231	antitubercular agent

Related Drugs by ATC class:

J04AK Other drugs for treatment of tuberculosis 7 drugs

bedaquilinedelamanidethambutolmorinamidepretomanidpyrazinamidethioacetazone

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.06	acidic
pKa2	7.66	acidic
pKa3	3.32	Basic
pKa4	2.72	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D07247	KEGG_DRUG
C0145184	UMLSCUI
CHEBI:135278	CHEBI
CHEMBL2107553	ChEMBL_ID
DB12954	DRUGBANK_ID
C100142	MESH_SUPPLEMENTAL_RECORD_UI
65720	PUBCHEM_CID
14307	IUPHAR_LIGAND_ID
1707	INN_ID
1199LEX5N8	UNII
57047	RXNORM
005992	NDDF
38722811000001108	SNOMEDCT_US

Pharmaceutical products:

None